Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes

K. Ordog\textsuperscript{a,b}, O. Horvath\textsuperscript{a,b}, K. Eros\textsuperscript{b,c,d}, K. Bruszt\textsuperscript{a,b}, Sz Toth\textsuperscript{a}, D. Kovacs\textsuperscript{c}, N. Kalman\textsuperscript{c}, B. Radnai\textsuperscript{c}, L. Deres\textsuperscript{a,b,d}, F. Gallyas Jr\textsuperscript{b,c,d}, K. Toth\textsuperscript{a,b}, R. Halmosi\textsuperscript{a,b,*}

\textsuperscript{a} 1st Department of Medicine, University of Pecs Medical School, Pecs, Hungary
\textsuperscript{b} Szentagothai Research Centre, University of Pecs, Pecs, Hungary
\textsuperscript{c} Department of Biochemistry and Medical Chemistry, University of Pecs Medical School, Pecs, Hungary
\textsuperscript{d} HAS-UP Nuclear-Mitochondrial Interactions Research Group, Budapest, Hungary

\textbf{A B S T R A C T}

\textbf{Aims:} During oxidative stress mitochondria become the main source of endogenous reactive oxygen species (ROS) production. In the present study, we aimed to clarify the effects of pharmacological PARP-1 inhibition on mitochondrial function and quality control processes.

\textbf{Main methods:} L-2286, a quinazoline-derivative PARP inhibitor, protects against cardiovascular remodeling and heart failure by favorable modulation of signaling routes. We examined the effects of PARP-1 inhibition on mitochondrial quality control processes and function in vivo and in vitro. Spontaneously hypertensive rats (SHRs) were treated with L-2286 or placebo. In the in vitro model, 150 \( \mu \text{M} \) \( \text{H}_2\text{O}_2 \) stress was applied on neonatal rat cardiomyocytes (NRCM).

\textbf{Key findings:} PARP-inhibition prevented the development of left ventricular hypertrophy in SHRs. The interbilibrar mitochondrial network were less fragmented, the average mitochondrial size was bigger and showed higher cristae density compared to untreated SHRs. Dynamin related protein 1 (Drp1) translocation and therefore the fission of mitochondria was inhibited by L-2286 treatment. Moreover, L-2286 treatment increased the amount of fusion proteins (Opa1, Mfn2), thus preserving structural stability. PARP-inhibition also preserved the mitochondrial genome integrity. In addition, the mitochondrial biogenesis was also enhanced due to L-2286 treatment, leading to an overall increase in the ATP production and improvement in survival of stressed cells.

\textbf{Significance:} Our results suggest that the modulation of mitochondrial dynamics and biogenesis can be a promising therapeutical target in hypertension-induced myocardial remodeling and heart failure.

1. Introduction

Nowadays one of the most important cardiovascular risk factor is hypertension, by which approximately 30\% of the adult population is affected globally [1]. Hypertension is associated with a significant risk of mortality and morbidity, because it can lead to coronary heart disease and its progression to heart failure [2–4].

Manifest heart failure has still very poor prognosis despite the broadened therapeutical possibilities [4]. Therefore, the prevention of heart failure is essential. Although activation of the neurohumoral system plays an important role in the development of myocardial remodeling, the intrinsic myocardial changes are of great importance, too. In cardiomyocytes of chronically stressed heart (e.g. hypertension), there is a lack in high-energy phosphates and simultaneously an increased reactive oxygen species production (ROS). Both the low energy supply and the oxidative stress as a consequence of mitochondrial dysfunction play an important role in the development of hypertensive heart disease and its progression to heart failure [5,6].

Mitochondria are the predominant source of energy in cardiomyocytes, however, under pathological conditions such as hypertension or heart failure they become the main source of endogenous ROS production, too [5,7,8]. Free radicals can cause wide variety of damages...
in the cells, e.g. single-strand DNA breaks, what activates poly(ADP-ribose) polymerase (PARP) enzymes. Activated PARP enzyme binds ADP-ribose polymers to the damaged DNA region, by cleaving NAD$^+$ to NAD$^+$. If the PARP enzyme is overactivated, the cellular NAD$^+$ stores are depleted, leading to a severe energy deficiency that causes programed or necrotic cell death [13,14]. H$_2$O$_2$ is considered as a relevant source of ROS in cells because it can yield in the production of hydroxyl radicals and therefore can cause oxidative cell injury by compromising the mitochondrial function and structure [15]. Hydrogen peroxide is a small and stable molecule which can easily pass through the membranes and induces oxidative injury in the cells, therefore it is the most common way for modeling oxidative stress situations in vitro [16,17].

Previously we have demonstrated that pharmacological PARP-inhibition protects against the development of postischemic-, hypertension-induced and toxic heart failure, as well as against hypertension-induced early cardiovascular damages (also known as hypertensive heart disease). Besides the orthodox effect of PARP-inhibition on NAD$^+$ preservation this protective effect was caused by favorable alterations of signaling routes [18–26]. In the present study, we aimed to clarify the effects of pharmacological PARP-1 inhibition on mitochondrial quality control processes and function.

2. Materials and methods

2.1. Materials

All chemicals for cell culture studies were purchased from Thermo Fisher Scientific and Gibco (Life Technologies, Carlsbad, CA, USA). Protease and phosphatase inhibitor cocktails and hydrogen peroxide were obtained from Sigma Aldrich Co. (St. Louis, MO, USA), NP-40 lysis buffer was purchased from Amresco (VWR International, Radnor, PA, USA). L-2286 was a gift of the Department of Organic and Pharmacological Chemistry, University of Pecs Medical School. MitoTracker Red CMXRos fluorescent dye was bought from Molecular Probes (Life Technologies, Carlsbad, CA, USA), JC-1 was obtained from Enzo Life Sciences (Enzo Biochem Inc., Farmingdale, NY, USA). The primary antibodies were purchased from Cell Signaling Technologies (Danvers, MA, USA), Novus Biologicals (Bio-Technne, Minneapolis, MN, USA), Abcam (Cambridge, UK), and Thermo Fisher Scientific (Life Technologies, Carlsbad, CA, USA). The horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA), XFeP Cell Mito Stress Test Kit, XF Calibrate and XF Base Medium, Brilliant II QPCR Master Mix and PfuUltra II Hotstart PCR Master Mix were obtained from Agilent Technologies (Santa Clara, CA, USA). The primers for PCR reactions were purchased from Bio-Science Medium, Brilliant II QPCR Master Mix and PfuUltra II Hotstart PCR Master Mix were obtained from Bio-Science Ltd. (Budapest, Hungary). EvaGreen™ dye was obtained from Biotium (Biotium, Hayward, CA, USA). All reagents were of the highest purity commercially available.

2.2. Ethics statement

The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health and was approved by the Animal Research Review Committee of the University of Pecs, Medical School (BA02/2000-2/2010).

2.3. Animal model and experimental protocol

10-week-old male spontaneously hypertensive (SHR) and Wistar Kyoto rats (WKY) were purchased from Charles River Laboratories (Wilmington, MA, USA) and were kept as we published earlier [24]. SHR rats were randomized into two groups: one group received no treatment (SHR-C, n = 8), whereas the other group (SHR-L, n = 8) received 5 mg/kg/day L-2286, a water-soluble PARP-inhibitor for 32 weeks. The third was an age-matched normotensive control group (WKY, n = 8). L-2286 was dissolved in the drinking water based on preliminary data about the

volume of daily fluid consumption. Rats were inspected weekly to measure their weight as well as to observe their normal activity, respiration, responsiveness to manipulations and general aspects. At the end of the study animals were euthanized with an overdose of ketamine hydrochloride intraperitoneally and heparinized with sodium heparin (100 IU/rat i.p., Biochemie GmbH, Kundl, Austria).

2.4. Non-invasive evaluation of cardiac functions and dimensions

All animals were examined by echocardiography to exclude rats with any heart abnormalities. Transthoracic two-dimensional echocardiography was performed under inhalation anesthesia. Rats were lightly anesthetized with a mixture of 1.5% isoflurane (Forame, Abbott Laboratories, Hungary) and 98.5% oxygen. The chest of animals was shaved, acoustic coupling gel was applied, and warming pad was used to maintain normothermia. Cardiac dimensions and functions were measured from short- and long-axis views at the mid-papillary level by VEVO 770 high-resolution ultrasound imaging system (VisualSonics, Toronto, Canada) equipped with a 25 MHz transducer. Ejection fraction (EF), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and the thickness of septum and posterior wall were determined.

2.5. Non-invasive blood pressure measurement

Blood pressure measurement were performed on each animal on two occasions at week 0 and 32 of the treatment period. Blood pressure measurement were performed by a non-invasive tail-cuff method by Hatteras SCl000 Blood Pressure Analysis System with rat species platform (Panlab, Harvard Apparatus; LE5001).

2.6. Determination of plasma B-type natriuretic peptide

After the sacrifice, blood samples were collected into Lavender Vacutainer tubes containing EDTA and aprotinin (0.6 IU/mL of blood) and were centrifuged at 1600 g for 15 min at 4 °C to separate the plasma. Supernatants were collected and BNP-45 were determined by ELISA method as the manufacturer proposed (BNP-45, Rat ELISA Kit, Abcam, Cambridge, UK).

2.7. Electron microscopic examination of hearts

For electron microscopic analysis, hearts were perfused retrogradely through the aortic root with ice-cold PBS to wash away blood and then washed by modified Kranovsky fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M Na-cacodylate buffer, pH 7.4 and 3 mM CaCl$_2$). The electron microscopic samples were prepared as described earlier [27], and they were examined with a JEOL 1200EX-II electron microscope. Four animals of each group, 3–5 block from each animal were used. The area of interfibrillar mitochondria (IFM) were measured by free hand polygon selection (n ~ 500/group) using the NIH ImageJ software, where length of longitudinal axes and numbers of mitochondrial cristae were also evaluated.

2.8. Western blot analysis

The preparation of total Western blot samples from cardiac tissue were performed as described earlier [27]. Fractionated western blot sample preparation from cardiac tissue was performed using ice-cold isolation solution (150 mM NaCl, 5 mM TRIS, 1 mM EDTA, protease inhibitor 1:100, phosphatase inhibitor 1:100). Heart tissue was minced, samples were disrupted on ice with Turrax and then with Potter-Elvehjem tissue homogenizer. Samples were centrifuged for 12 min at 750g, then the supernatant, which was containing the cytosolic and mitochondrial fraction, was aspirated, the precipitated nucleus fraction was discarded. The supernatant was centrifuged for 12 min at 11,000g.
Table 1

| Effect of L-2286 on echocardiographic parameters and on BNP level. WKY: 42-week-old normotensive age-matched animals, n = 8; SHR-C: 42-week-old non-treated spontaneously hypertensive (SHR) rats, n = 8; SHR-L: 42-week-old SHR rats received L-2286 for 32 weeks, n = 8. EF: ejection fraction, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume. Septum: thickness of septum, PW: thickness of posterior wall, SBP: systolic blood pressure, HR: heart rate, VW/BW: ventricular weight to body weight ratio. Values are mean ± SEM. *p < 0.01 vs. WKY, †p < 0.05 vs. SHR-C.

<table>
<thead>
<tr>
<th></th>
<th>WKY</th>
<th>SHR-C</th>
<th>SHR-L</th>
</tr>
</thead>
<tbody>
<tr>
<td>EF (%)</td>
<td>70.24 ± 1.12</td>
<td>67.21 ± 1.22</td>
<td>69.13 ± 1.84</td>
</tr>
<tr>
<td>LVEDV</td>
<td>286.78 ± 10.78</td>
<td>350.78 ± 10.78</td>
<td>329.67 ± 10.78</td>
</tr>
<tr>
<td>LVESV</td>
<td>9.93</td>
<td>11.02 ± a</td>
<td>12.53 ± b</td>
</tr>
<tr>
<td>Septum</td>
<td>115.11 ± 5.96</td>
<td>101.32 ± 3.34 b</td>
<td></td>
</tr>
<tr>
<td>PW</td>
<td>3.01 ± 0.16</td>
<td>3.97 ± 0.22</td>
<td>3.38 ± 0.3 b</td>
</tr>
<tr>
<td>LV weight</td>
<td>1393 ± 13.3</td>
<td>1168 ± 45.9 b</td>
<td></td>
</tr>
<tr>
<td>SBP100%</td>
<td>128 ± 4.6</td>
<td>231 ± 6.3</td>
<td>225 ± 2.4</td>
</tr>
<tr>
<td>HR (beats min⁻¹)</td>
<td>308 ± 13</td>
<td>339 ± 7.8</td>
<td>335 ± 9.2</td>
</tr>
<tr>
<td>VW/BW</td>
<td>3.48 ± 0.52</td>
<td>3.87 ± 0.24</td>
<td>4.87 ± 0.21</td>
</tr>
<tr>
<td>BNP (ng/mL)</td>
<td>2.06 ± 0.15</td>
<td>2.35 ± 0.03</td>
<td>2.23 ± 0.13</td>
</tr>
</tbody>
</table>

To gain the cytosolic fraction in the supernatant and mitochondrial fraction in the precipitate, samples were harvested separately in 2× SDS-polyacrylamide gel electrophoresis sample buffer and denatured at 95 °C for 5 min. Electrophoresis and transfer of proteins were performed as described earlier [24]. Membranes were probed overnight at 4 °C with antibodies recognizing the following antigens: dynamin-related protein 1 (Drp1) (1:1000), optic atrophy 1 (Opa1, 1:1000), anti poly(ADP-ribose) (anti-PAR, 1:5000). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, for whole cell and cytoplasmic fraction) and pyruvate dehydrogenase complex (PDC, for mitochondrial fraction) were used as loading controls. Antibodies were purchased from Cell Signaling Technology, except for anti-PAR, from Alexis Biotechnology (London, UK). After scanning, results were quantified by the NIH Image J program. Densities of bands were normalized to the respective loading controls.

2.9. Neonatal rat cardiomyocyte (NRCM) cell culture

Cardiomyocytes were isolated from 1 to 3 days old neonatal Wistar rats using the Pierce™ Primary Cardiomyocyte Isolation Kit (Life Technologies, Carlsbad, CA, USA) following the manufacturer’s instructions. The animals were sacrificed and then their hearts were removed and minced into 1–3 mm³ pieces. The pieces were digested with an enzyme complex (Cardiomyocyte Isolation Enzyme 1 (with papain) and Cardiomyocyte Isolation Enzyme 2 (with thermolysin)). Purified NRCM cells were maintained in a humidified 5% CO₂ atmosphere at 37 °C, cells were cultured in specific Dulbecco’s modified Eagle Medium (DMEM) for Primary Cell Isolation containing 10% fetal bovine serum (FBS) and antibiotic solution (1% penicillin and streptomycin solution).

2.10. Evaluation of the mitochondrial fragmentation

NRCM cells were seeded at a density of 10⁶ cells/well in 6-well plates on glass coverslips with gelatin coating and cultured for at least 2 days before experiment. On the day of experiment, cells were washed once with PBS and fresh medium was added, then cells were treated with either H₂O₂ with or without L2286. Group of cells: Control; cells without any treatment, Control-L-2286: cells incubated with 10 μM L-2286 for 0.5 h, H₂O₂: cells stressed with 150 μM H₂O₂ for 0.5 h, H₂O₂ + L-2286: cells stressed with 150 μM H₂O₂ and treated with 10 μM L-2286 for 0.5 h. After the appropriate treatment coverslips were rinsed in PBS and were added 300 nM MitoTracker Red CMXRos dissolved in PBS and incubated for 30 min at 37 °C. After incubation, coverslips were rinsed in PBS then imaged with a Nikon Eclipse Ti-U fluorescent microscope equipped with a Spot RT3 camera using a 60x objective and epifluorescent illumination.

2.11. Immunoblot analysis

NRCM cells were seeded into a 6-well plate and cultured. After the appropriate treatment, cells were harvested, the cell pellet was suspended in ice-cold PBS buffer, then centrifuged for 5 min at room temperature at 1200 rpm. The pellets were suspended in 300 μL NP-40 lysis buffer (Amresco, J619) containing protease and phosphatase inhibitor cocktail (1:100). The samples were shaken for 30 min at 4 °C and then centrifuged for 20 min (4 °C, 12,000 rpm). To each sample, 4x concentrated sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis sample buffer was added. Proteins were separated on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. After blocking (1 h with 5% non-fat dry milk in Tris-buffered saline), membranes were probed overnight at 4 °C with primary antibody. We used the following antibodies and dilutions: anti-GAPDH (Cell Signaling Technology, 2118L, 1:1000), anti-Drp1 (Cell Signaling Technologies, 8570S, 1:1000), anti-phospho-Drp5016 (Cell Signaling Technologies, 12282S, 1:500), anti-phospho-Dnp3017 (Cell Signaling Technologies, 4867S, 1:500), anti-mitosufin1 (Mfn1, Abcam, ab57602, 1:1000), anti-mitosufin2 (Mfn2, Cell Signaling Technologies, 9482S, 1:1000), anti-Opa1 (Cell Signaling Technologies, 80471S, 1:1000), anti-mitochondrial fission protein 1 (TTC11/Fis1, Abcam, ab71498, 2 μg/ml), anti-PDC (Thermo Fisher Scientific, PA5–66472, 1:1000), anti-peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α, Novus Biologicals, NBPI-04676, 1:1000), anti-cAMP response element-binding protein (CREB, Cell Signaling Technology, 4820S, 1:1000), anti-phospho-CREBser135 (Cell Signaling Technologies, 9198S, 1:1000), anti-voltage dependent anion channel (VDAC, Cell Signaling Technologies, 4661S, 1:1000), anti-NADH dehydrogenase Fe-S protein 1 (NDFUs1, Novus Biologicals, NBPI-31142, 1:1000), anti-Ubiquinol-cytochrome c reductase core protein 1 (UCRC1, Novus Biologicals, NBPI-03825, 1:1000), anti-Microtubule-associated protein 1 light chain 3 alpha (LC3A, Novus Biologicals, NB100-2331, 1:1000), anti-Poly (ADP-ribose) polymerase (PARP, Cell Signaling Technologies, 9532S, 1:1000). Membranes were washed 6-times for 5 min in Tris-buffered saline containing 0.1% Tween-20 before addition of appropriate horseradish peroxidase-conjugated secondary antibody (goat anti-rabbit IgG, Sigma Aldrich Co. A0545, 1:3000 dilution; rabbit anti-mouse IgG, Sigma Aldrich Co., A9044, 1:5000 dilution). Membranes were washed again as before, and then antibody-antigen complexes were visualized by enhanced chemiluminescence. The results of western blots were quantified by the ImageJ software (NIH, Bethesda, MD, USA). Each experiment was repeated three times with similar results.

2.12. Capillary Western immunoassay (Protein Simple Wes)

Capillary Western immunoassay was performed on a Protein Simple Wes system according to the manufacturer’s instructions using a 12–240 kDa Separation Module (Bio-Techne R&D Systems, SM-W004) and the Anti-Rabbit Detection Module (DM-001). Fractionated NRCM samples were made as described in Section 2.5. NRCM samples were diluted to an appropriate concentration (0.3 mg/mL) in the sample buffer (100x diluted ‘10x Sample Buffer 2’ from the Separation Module), then mixed with prepared Fluorescent Master Mix and heated at 95 °C for 5 min. The ladder, the samples, blocking reagent, primary and HRP-conjugated secondary antibodies, and the luminol-peroxide mixture as chemiluminescent substrate were pipetted into the plate. Instrument default settings were used: stacking and separation at 475 V for 30 min; blocking reagent for 5 min; primary and secondary antibody both for 30 min; Luminol/peroxide chemiluminescence detection were used in high dynamic range function. Compass software was used to
process and analyze all data results.

2.13. JC-1 assay for mitochondrial membrane potential measurement

The mitochondrial membrane potential ($\Delta \Psi_m$) was measured using the mitochondrial membrane potential specific fluorescent probe, JC-1 (Enzo Life Sciences, ENZ-52304). The procedure is based on tracking the fluorescence shift from red to green, the J-aggregates located in mitochondrial matrix and converted to J-monomers while translocated through the mitochondrial permeability transition pore into the cytosol. NRCM cells were seeded onto glass coverslips coated with gelatin and cultured at least 2 days before the experiment. After treatment, cells were washed in PBS and then incubated for 15 min at 37°C in media containing 2 μg/mL JC-1. The dye emits green fluorescence (530 nm) at low $\Delta \Psi_m$ and red (590 nm) at high $\Delta \Psi_m$. Following incubation, the cells were washed once with PBS and then imaged with a Nikon Eclipse Ti-U fluorescent microscope equipped with a Spot RT3 camera using a 60× objective and epifluorescent illumination. All experiments were repeated three times. Fluorescent signals were quantified by using the ImageJ software (NIH, Bethesda, MD, USA).

2.14. Determination of mitochondrial oxygen consumption rate

Agilent Seahorse XFp Analyzer (Santa Clara, CA, USA) was used to determine the NRCM cells’ oxygen consumption rate (OCR). Cell Mito Stress Kit is capable of real-time monitoring of mitochondrial oxygen consumption by examining the mitochondrial respiratory chain.
complexes. NRCM cells were seeded in Xfp Miniplate at the density of 10^5 cells/well in 80 μL complete growth medium (DMEM for Primary Cell Isolation containing 10% FBS and 1% antibiotic solution) and incubated at 37 °C, 5% CO\(_2\) for 2 days. On the day before the assay, the Xfp Sensor Cartridge was hydrated in XF Calibrant in non-CO\(_2\) incubator at 37 °C overnight. On the day of the assay, after subjecting cells to the appropriate treatment, complete growth medium was removed and replaced with assay medium supplemented with 1 mM pyruvate, 2 mM glutamine, 10 mM glucose, pH 7.4. Before measurement oligomycin, FCCP and rotenone/antimycin A were loaded in the injection ports of the sensor cartridge. These compounds’ final concentration was 1 μM and three measurements were taken after each injection.

2.15. Quantification of mitochondrial DNA (mtDNA) damage and relative mitochondrial DNA content by real-time PCR

NRCM cells were used as the source of DNA for all experiments, and cells were grown in special DMEM with 10% FBS. After the appropriate treatment total DNA was isolated using GenElute™ Mammalian Genomic DNA Miniprep kit (Sigma Aldrich Co., St. Louis, MO, USA, G1N70). The following rat primer sequences were used: LRPCR (14,958 bp) forward: 5′-ATTTTCTCCCAGTTACGAAAG-3′, reverse: 5′-CTTGGTAAGTAAATTTCTTTCTCC-3′; SRPCR (210 bp) forward: 5′-GCTGAATTAGCGAAGGGGTAC-3′; reverse: 5′-TGCCACTCCCAAAGTAAAGGTCATACTC-3′. Crossing points were automatically generated by the software and calculation of mitochondrial DNA (mtDNA) damage was made using the ΔΔCt method.

Fig. 3. Hypertension related fragmentation of interfibrillar mitochondria in the myocardium. Distribution of mitochondria based on their size in various area range groups: (A) WKY: normotensive age-matched animals, (B) SHR-C: non-treated spontaneously hypertensive (SHR) rats, (C) SHR-L: SHR rats treated by L-2286. (D) Mean mitochondrial area (E) Longitudinal axis of mitochondria. Values are means ± S.E.M. **p < 0.01 vs. SHR-C, ***p < 0.01 vs. WKY.

2.16. Analysis of citrate synthase activity and glutathione level in NRCM cells

NRCM cells were seeded at a density of 10^5 cells/well in 6-well plates and cultured. After the appropriate treatment, cells were harvested, the cell pellet was suspended in ice-cold citrate synthase or GSH cell lysis buffer, then centrifuged for 5 min at 4 °C at 10,000 ×g, then the supernatant was collected for further use. Citrate synthase was measured using a Bio Rad CFX96 Touch Real-Time PCR Detection System. Short fragment, cytochrome c oxidase subunit 1 (COX1), cytochrome c oxidase subunit 3 (COX3) and β-actin were done using a Brilliant QPCR Master Mix, while LRPCR was done using PfuUltra™ II Fusion HS DNA Polymerase. The final SRPCR, COX1, COX3 and β-actin cycling parameters were: 10 min at 95 °C followed by 30 s at 95 °C, 1 min at 60 °C, 30 s at 72 °C for 40 cycles. The final LRPCR cycling parameters were: 2 min at 92 °C followed by 15 s at 92 °C, 30 s at 50 °C, 8 min at 68 °C for 40 cycles. The relative mitochondrial DNA content was determined by real-time PCR, using COX1 and COX3 primaries, normalized to a nuclear-encoded β-actin gene. The following rat primer sequences were used: COX1 (199 bp) forward: 5′-CACAGTGGGGGCTCAAAGC-3′, reverse: 5′-CGTAGTAGACAGACAATTAGG-3′; COX3 (244 bp) forward 5′-TCAGGAGTCTCAATTACATG-3′, reverse: 5′-GCTGAATTAGCGAAGGGGTAC-3′; β-actin (191 bp) forward 5′-GCGGTGACCATAGCCCTCTTT-3′, reverse: 5′-TGCCACTCCCAAAGTAAAGGTCATACTC-3′. Crossing points were automatically generated by the software and calculation of mitochondrial DNA (mtDNA) damage was made using the ΔΔCt method.
using a kit from Sigma Aldrich (MAK193) following the manufacturer’s instruction. The absorbance was recorded at 412 nm every 5 min for 50 min. The colorimetric product (GSH) was proportional to the enzymatic activity of citrate synthase and normalized to the quantity of cells. Glutathione was measured using a kit from PromoCell (PK-CA577-K251) following the manufacturer’s instructions. The amount of total glutathione was detected using a fluorometric plate reader (Ex./Em. = 380 nm/460 nm).

2.17. Statistical analysis

All data were expressed as means ± standard error of mean (SEM). First, the homogeneity of the groups was tested by F-test (Levene’s test). There were no significant differences among the groups. Comparisons between groups were made using the one-way ANOVA test followed by post hoc correction in SPSS for Windows, version 21.0. The Student’s t-test was used to compare the mean values of two groups. A value of \( p < 0.05 \) was considered statistically significant.

3. Results

3.1. PARP inhibition decreased the left ventricular hypertrophy in spontaneously hypertensive rats

At the beginning of the study the echocardiographic parameters of the three groups did not differ significantly from each other (data not shown). At the age of 42 weeks there was no significant difference in LV systolic function (EF) between the WKY and SHR groups yet. Heart rate did not differ significantly during the anesthesia among the groups. LVEF and LVEDV were increased significantly in SHRs \(( p < 0.01 \text{ WKY vs. SHR-C and SHR-L})\), and these unfavorable alterations were slightly reduced by L-2286 treatment \(( p < 0.05 \text{ SHR-L vs SHR-C})\). The thickness of the septum and posterior wall as well as the left ventricular weight were also increased in SHR groups (indicating the presence of ventricular hypertrophy) comparing to the WKY group \(( p < 0.01 \) ), and these parameters could be significantly reduced by the administration of the PARP-inhibitor L-2286 \(( p < 0.05 \text{ SHR-L vs. SHR-C group})\) (Table 1). Moreover, the degree of myocardial hypertrophy was also determined by ventricular weight to body weight ratio (VW/BW, mg/g). This parameter was significantly increased in SHR groups compared to WKY group, but the L-2286 treatment ameliorated this detrimental effect in SHR-L group in comparison to SHR-C group.

Similarly to ejection function in the case of lung wet weight to dry weight ratio (a measure of heart failure), we did not find any significant changes among the groups.

Non-invasive systolic blood pressure measurements of animals were performed to validate hypertension and to demonstrate that L-2286 treatment did not have any significant effects on systolic blood pressure of chronic hypertensive animals (Table 1).

3.2. Plasma BNP level in young hypertensive animals

Only slightly elevated plasma BNP levels were found in SHR-C and SHR-L groups \((\text{NS vs. WKY group})\), which means that at this stage of hypertensive heart disease there is no heart failure yet. Of course, the difference between the hypertensive groups was also not significant (Table 1).

3.3. The effect of L-2286 treatment on the activity of PARP enzyme

To detect the effectivity of L-2286 treatment on PARP activity, the auto-PARylation of the PARP-1 enzyme was analyzed in each total western blot sample. The highest degree of poly(ADP-ribosyl)ation was present in the SHR-C group \(( p < 0.01 \text{ vs. WKY})\). L-2286 treatment in the applied dose caused a prominent and significant decrease in the PARP-1 auto-PARylation \(( p < 0.01 \text{ SHR-L vs. SHR-C})\) (Fig. 1).

3.4. Effect of PARP inhibition on the structure of interfibrillar mitochondria

Longitudinal sections of myofibrils were evaluated to assess the status of the interfibrillar mitochondria by electron microscopy. In the
3.5. The effect of L-2286 treatment on the size of mitochondria

The whole range of the mitochondrial areas that was found in cardiomyocytes was divided into seven equal ranges of 0.3 μm², in which the relative frequency of mitochondria was determined. Only less than 1% of mitochondria were extremely large (area more than 2.1 μm²) in each group of animals. In the WKY group the most common mitochondrial area range was the 0.3–0.6 μm² range (Fig. 3A). In hypertensive control animals (Fig. 3B) half of the measured mitochondria belonged to the lowest area range (<0.3 μm²), however in the WKY group only approx. 20% of mitochondria pertained into this area range. This result indicates a more fragmented phenotype of interfibrillar mitochondria due to hypertension-induced myocardial remodeling and oxidative stress. In L-2286-treated hypertensive animals, however, the distribution of the size of mitochondria was similar to the WKY group, and most mitochondria belonged to the 0.3–0.6 μm² area range (Fig. 3C).

The changes in the mitochondrial size can also be assessed by determining the mean area or the length of mitochondria in each group. Significantly lower values could be seen in the SHR-C group compared to the normotensive group (p < 0.05 SHR-C vs. WKY) (Fig. 3D). Regarding both the mean area and longitudinal axis of mitochondria, a significant decrease was apparent in the SHR-C group (p < 0.01, SHR-C vs. WKY) compared to the normotensive group (Fig. 3E). The worsening of these parameters were less pronounced in SHR animals treated by L-2286 (p < 0.01, SHR-L vs. SHR-C) (Fig. 3C, D, E).

3.6. The effect of L-2286 treatment on the subcellular distribution of mitochondrial dynamics-related proteins

Opal was not detected in the cytosolic fraction. In mitochondrial fractions of SHR-C samples the Opal level was decreased significantly compared to normotensive animals (p < 0.01, SHR-C vs. WKY). L-2286 treatment did not influence significantly the decrease of Opal level in mitochondria (Fig. 4A-C). Chronic hypertension induced myocardial remodeling did not have any significant effect on overall cellular amount of Drp1 protein in our animal model. Neither did the L-2286 treatment cause any significant alteration in Drp1 protein level (data not shown). To assess the intracellular distribution of Drp1 protein between the cytosolic and mitochondrial compartments, fractionated western blot samples were used. In cytosolic fractions, Drp1 level was the lowest in the non-treated hypertensive control group (p < 0.01, SHR-C vs. WKY) (Fig. 4A, D). Inhibition of PARP-1 by L-2286 treatment retained a higher amount of Drp1 in the cytosol (p < 0.01 SHR-L vs. SHR-C). On the other hand, the greatest translocation of Drp1 into the mitochondria could be seen in the SHR-C group (p < 0.01, SHR-C vs. WKY) (Fig. 4B, D). L-2286 treatment reduced the level of Drp1 in the mitochondrial fraction (p < 0.05, SHR-L vs. SHR-C).

3.7. The effect of L-2286 treatment on glutathione level and on auto-PARYlation in NRCM cells

During oxidative stress there is a decrease in level of GSH, thus GSH/GSSG ratio also decreases. In our experiments H₂O₂ induced a significant decrease in GSH level of NRCM cells, indicating oxidative damage. L-2286 treatment on the other hand ameliorated this detrimental effect of oxidative stress (Fig. 5A). To detect the effectivity of L-2286 treatment, the activity of ADP-ribosylation processes were analyzed by capillary western blot in NRCM cell samples. The most pronounced auto-PARYlation was seen in H₂O₂ samples (Fig. 5A). The whole range of the mitochondrial areas that was found in cardiomyocytes was divided into seven equal ranges of 0.3 μm², in which the relative frequency of mitochondria was determined. Only less than 1% of mitochondria were extremely large (area more than 2.1 μm²) in each group of animals. In the WKY group the most common mitochondrial area range was the 0.3–0.6 μm² range (Fig. 3A). In hypertensive control animals (Fig. 3B) half of the measured mitochondria belonged to the lowest area range (<0.3 μm²), however in the WKY group only approx. 20% of mitochondria pertained into this area range. This result indicates a more fragmented phenotype of interfibrillar mitochondria due to hypertension-induced myocardial remodeling and oxidative stress. In L-2286-treated hypertensive animals, however, the distribution of the size of mitochondria was similar to the WKY group, and most mitochondria belonged to the 0.3–0.6 μm² area range (Fig. 3C).

The changes in the mitochondrial size can also be assessed by determining the mean area or the length of mitochondria in each group. Significantly lower values could be seen in the SHR-C group compared to the normotensive group (p < 0.05 SHR-C vs. WKY) (Fig. 3D). Regarding both the mean area and longitudinal axis of mitochondria, a significant decrease was apparent in the SHR-C group (p < 0.01, SHR-C vs. WKY) compared to the normotensive group (Fig. 3E). The worsening of these parameters were less pronounced in SHR animals treated by L-2286 (p < 0.01, SHR-L vs. SHR-C) (Fig. 3C, D, E).

3.6. The effect of L-2286 treatment on the subcellular distribution of mitochondrial dynamics-related proteins

Opal was not detected in the cytosolic fraction. In mitochondrial fractions of SHR-C samples the Opal level was decreased significantly compared to normotensive animals (p < 0.01, SHR-C vs. WKY). L-2286 treatment did not influence significantly the decrease of Opal level in mitochondria (Fig. 4A-C). Chronic hypertension induced myocardial remodeling did not have any significant effect on overall cellular amount of Drp1 protein in our animal model. Neither did the L-2286 treatment cause any significant alteration in Drp1 protein level (data not shown). To assess the intracellular distribution of Drp1 protein between the cytosolic and mitochondrial compartments, fractionated western blot samples were used. In cytosolic fractions, Drp1 level was the lowest in the non-treated hypertensive control group (p < 0.01, SHR-C vs. WKY) (Fig. 4A, D). Inhibition of PARP-1 by L-2286 treatment retained a higher amount of Drp1 in the cytosol (p < 0.01 SHR-L vs. SHR-C). On the other hand, the greatest translocation of Drp1 into the mitochondria could be seen in the SHR-C group (p < 0.01, SHR-C vs. WKY) (Fig. 4B, D). L-2286 treatment reduced the level of Drp1 in the mitochondrial fraction (p < 0.05, SHR-L vs. SHR-C).

3.7. The effect of L-2286 treatment on glutathione level and on auto-PARYlation in NRCM cells

During oxidative stress there is a decrease in level of GSH, thus GSH/GSSG ratio also decreases. In our experiments H₂O₂ induced a significant decrease in GSH level of NRCM cells, indicating oxidative damage. L-2286 treatment on the other hand ameliorated this detrimental effect of oxidative stress (Fig. 5A). To detect the effectivity of L-2286 treatment, the activity of ADP-ribosylation processes were analyzed by capillary western blot in NRCM cell samples. The most pronounced auto-PARYlation was seen in H₂O₂ samples, however the L-2286 treatment alleviated this unfavorable effect (Fig. 5B).

3.8. Morphological changes in the mitochondrial network

In control NRCM cells the mitochondrial reticulum was normal with long, regular shape (Fig. 6A). However, oxidative stress induced marked
morphological changes, the mitochondrial network became fragmented, and consequently small, dot-like mitochondria could be observed (Fig. 6C). L-2286 treatment protected the mitochondrial network against oxidative stress induced damage in NRCMs, and therefore the mitochondrial network remained reticular, similarly to the control cells (Fig. 6D).

3.9. Effect of L-2286 on cellular levels and subcellular distribution of fission-fusion regulator proteins

Our data showed that L-2286 treatment causes significant increase in the amount of the mitochondrial fusion proteins Mfn2 and Opa1 compared to the stressed group, and also compared to the control group (p < 0.01 H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$ and vs. Control) (Fig. 7A and B), but no significant change was observed in the expression level of Mfn1 protein (Fig. 7C).

Due to L-2286 treatment, the level of mitochondrial fission proteins, Drp1 (p < 0.05) and Fis1 (p < 0.01) showed a marked decrease as compared to the stressed group (Fig. 8A and B), where these values were the highest (p < 0.01 H$_2$O$_2$ vs. Control). We examined the phosphorylation state of Drp1 protein too, because the phosphorylation of Drp1 at Serine 616 residues promotes mitochondrial fission, however, the phosphorylation of the Drp1 Serine 637 residue inhibits the enzyme activity and its translocation into the mitochondria. We have proved that L-2286 treatment causes significant decrease in the phosphorylation state of Drp1 at Serine 616 residues (p < 0.01, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$ group), moreover PARP-inhibition causes considerable increase in phosphorylation state of Drp1 at Serine 637 residue compared to stressed group (p < 0.01, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$) (Fig. 8C and D).

We also aimed to determine the subcellular distribution of Drp1 and Opa1 proteins between the cytosolic and mitochondrial compartments of NRCMs, to gain insight into the molecular background of attenuated fission processes and preserved inner mitochondrial membrane structure. Opa1 is not detectable in the cytosol (Fig. 9B). However, in the mitochondrial fraction of L-2286 treated stressed cells the level of Opa1 increased significantly (Fig. 9A) compared to stressed only group (p < 0.01, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$). The amount of cytosolic Drp1 in the stressed only group (H$_2$O$_2$) was the lowest. Inhibition of PARP-1 by L-2286 treatment retained a significantly higher amount of Drp1 in the cytosol (p < 0.01 H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$). Therefore, it could be stated that the intracellular Drp1 localization was greatly influenced by PARP-inhibition, because the level of Drp1 protein was significantly lower in the mitochondrial fraction and higher in the cytosolic fraction of treated cells (Fig. 9B) compared to stressed only NRCM cells (p < 0.01, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$).

3.10. Examination of mitochondrial function via membrane potential and oxygen consumption rate

We examined the effect of PARP-inhibition on mitochondrial membrane potential using JC-1, a cell-permeable voltage-sensitive fluorescent mitochondrial dye (Fig. 10). JC-1 emits red fluorescence if the mitochondrial membrane potential is high (aggregated dye), while depolarized mitochondria emit green fluorescence (monomer dye). Fluorescent microscopy showed strong red and weak green fluorescence in the control group, which indicates normal, healthy mitochondrial membrane potential (high ΔΨm). Mitochondrial membrane depolarized due to H$_2$O$_2$ stress, resulting in weaker red and stronger green fluorescence. The addition of L-2286 to hydrogen peroxide stressed cells, the decrease in the mitochondrial membrane potential was found to be smaller, therefore red and green fluorescence values were similar to that of control cells (Fig. 10A). Quantifying these changes (Fig. 10B) we...
could observe that the mitochondrial membrane potential is reduced due to oxidative stress (p < 0.05, H$_2$O$_2$ vs. Control), and this unfavorable change was moderated by L-2286 treatment in our cell culture model (p < 0.05, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$).

To determine the mitochondrial energy metabolism and respiratory function, we used the Agilent Seahorse XFp Analyzer system and the Agilent Seahorse XFp Cell Mito Stress Test (Fig. 11 A and B). L-2286 itself had no effect on the rate of mitochondrial respiration. However, we observed that (Fig. 11 A) H$_2$O$_2$ treatment decreased the basal respiration, the maximal respiration, the spare respiratory capacity and the ATP production as a result of H$_2$O$_2$-induced oxidative damage compared to the Control group (p < 0.05, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$).

To support more precisely the effect of PARP-inhibition on mitochondrial biogenesis and enhanced cellular amount of mitochondria, further investigations were made. The electron transfer chain complexes located on the inner mitochondrial membrane are essential for mitochondrial function. We measured the level of NDUFs1 and UQCRC1 proteins, which are subunits of the respiratory chain proteins NADH-ubiquinone oxidoreductase and Ubiquinol Cytochrome c Reductase (Fig. 12 D and E). Our results showed that hydrogen peroxide caused a significant decrease in the amount of NDUFs1 and UQCRC1 proteins compared to non-stressed cells (p < 0.05, H$_2$O$_2$ vs. Control). In addition, hydrogen-peroxide stress with L-2286 treatment prevented this decrease.
decrease, moreover the highest NDUFs1 and UQCRC1 level could be seen in this group (p < 0.01, H2O2 vs. H2O2 + L-2286).

The relative mitochondrial DNA content was determined by “real-time” PCR, using COX1 and COX3 primers, normalized to a nuclear-encoded β-actin gene. We found that L-2286 treatment increased the relative expression level of both tested genes (Fig. 12 G and H). Moreover, we investigated the citrate synthase activity in NRCM cells. Citrate synthase (CS) activity was reduced in hydrogen-peroxide stressed group approximately 55% compared to control group. In the L-2286 treated group, the citrate synthase activity was increased almost 20% in comparison to stressed group (Fig. 12 I).

Fig. 8. Effect of L-2286 treatment on mitochondrial fission mediators in NRCM cells. (A) Quantitative analysis of the amount of Drp1 protein, (B) Quantitative analysis of the Fis1 protein expression level, (C) Quantitative analysis of the phosphorylation of Drp1 S616 residues, (D) Quantitative analysis of the phosphorylation of Drp1 S637 residues. (E) Representative Western-blot pictures of Fis1, Drp1 levels as well as phosphorylation of phospho-Drp1S616 and phospho-Drp1S637 residues. GAPDH was used as loading control. Group of cells: Control: cells without any treatment, Control + L-2286: cells incubated with 10 μM L-2286 for 0.5 h, H2O2: cells stressed with 150 μM H2O2 for 0.5 h, H2O2 + L-2286: cells stressed with 150 μM H2O2 and treated with 10 μM L-2286 for 0.5 h. Values are means ± S.E.M, (n = 4). **p < 0.01 vs. Control group, *p < 0.01 vs. H2O2 group, *p < 0.05 vs H2O2 group.

Fig. 9. Effect of L-2286 on the intracellular distribution of Drp1 and Opa1 proteins. (A) Quantitative analysis of Opa1 level in mitochondrial fraction. (B) Representative capillary western immunoassay of Opa1 and Drp1 expression level is shown. GAPDH was used for cytosolic, PDC was used for mitochondrial fraction as loading control. (C) Quantitative analysis of the Drp1 protein level in cytosolic fraction. (D) Quantitative analysis of mitochondrial Drp1. Group of cells: Control: cells without any treatment, Control + L-2286: cells incubated with 10 μM L-2286 for 0.5 h, H2O2: cells stressed with 150 μM H2O2 for 0.5 h, H2O2 + L-2286: cells stressed with 150 μM H2O2 and treated with 10 μM L-2286 for 0.5 h. Values are means ± S.E.M, (n = 4), **p < 0.01 vs. Control group, *p < 0.05 vs. Control group, ##p < 0.01 vs. H2O2 group.
3.12. The effect of L-2286 treatment on mitochondrial genome integrity

In the present study we used H$_2$O$_2$ exposure as a toxic agent having DNA damaging potential. Using the real-time detection of long-range PCR (14,958 bp; LRPCR) and short-range (210 bp; SRPCR) we examined the impact of 150 μM H$_2$O$_2$ on mtDNA integrity. These data show that oxidative stress induced a significant damage of the mtDNA in the stressed group (p < 0.01 vs. Control group). In the treated group the mitochondrial DNA was less fragmented, its relative expression level showed a marked, almost 4-fold increase compared to the stressed group (p < 0.01, H$_2$O$_2$ + L-2286 vs. H$_2$O$_2$) (Fig. 13).

4. Discussion

The major finding of this study is that pharmacological PARP-inhibition protects against the development of hypertensive heart disease via the maintenance of physiological mitochondrial structure and function.

SHR model was used in our experiments as a relevant animal model of essential hypertension in humans [29,30]. Marked hypertensive heart failure developed in hypertensive animals by the end of the study (42 weeks), although without manifesting any signs of heart failure. These are in accordance with previous works in the literature [21,23,31]. In non-treated SHR animals the left ventricular wall thicknesses and calculated LV mass increased markedly compared to normotensive WKY rats. The volumes of left ventricle also increased, however, the systolic left ventricular function remained normal. In line with the unchanged EF, the heart failure biomarker BNP level was also practically unchanged (Table 1) [32]. PARP-inhibition caused a significant decrease in parameters indicating cardiac hypertrophy, what is also in accord with previous results [13,21,23].

Nowadays there is a substantial literature regarding the cytoprotective effects of PARP inhibition among various pathological conditions [33–35]. PARP-inhibitors beside their “orthodox” NAD+-preserving effect, can also influence several signal transduction pathways. It was proved, that they activate the prosurvival signaling (PI3K/Akt-1/GSK-3β, PKCδ), which in turn protects mitochondria and therefore the cell survival during oxidative stress [23,36]. In addition, PARP-inhibition
suppresses the activity of MAP kinases (JNK, p38 MAPK) through the enhanced MKP-1 production. MKP-1 downregulation, however, leads to increased JNK phosphorylation, and to the activation of mitochondrial fission and mitophagy and therefore to compromised mitochondrial energy production [23, 37, 38].

Moreover, the direct mitochondrial protective effect of PARP-inhibition was already confirmed by our workgroup in isolated mitochondria earlier [39].

This knowledge led us in our recent work to focus on the effects of PARP-inhibition on various mitochondrial processes as well as on structural and functional alterations of mitochondria during oxidative stress situations. The effectivity of the applied PARP-inhibitor (L-2286) was checked by measuring the auto-PARylation of the PARP enzyme (Fig. 1).

The interfibrillar mitochondria (IFM) having a profound role in supplying the energy demand of cardiac work physiologically tightly fills the space between the contractile elements of cardiomyocytes. In the myocardium of 42-week-old untreated SHRs (SHR-C), mitochondria became morphologically more heterogeneous, they were loosely arranged between the myofilaments, the dilation of cristae spaces was apparent, and the size of mitochondria was also decreased (Fig. 2). These alterations indicate a more fragmented phenotype of IFM due to chronic hypertension induced oxidative stress (Fig. 3). In contrast, in the myocardium of L-2286 treated SHRs (SHR-L) mitochondria were less fragmented, and they showed higher cristae density.

The fragmentation of mitochondria is regulated by the balance of fusion-fission processes. To monitor these processes, the amount and subcellular distribution of the main fusion promoter Opa1 and the fission-inducing factor Drp1 was determined (Fig. 4). In our animal model chronic hypertension did not have any significant effects on the cellular level of proteins playing a part in the fission and fusion. However, the subcellular distribution of Drp1 was altered, its translocation to the mitochondrial fraction increased, which is a starting point of provoking fragmentation of mitochondria. Drp1 translocation and therefore the fission of mitochondria was blocked by the L-2286.

To study the effect of PARP-inhibition on mitochondrial structure and function in a more detailed manner, in vitro experiments were carried out using hydrogen peroxide-induced severe oxidative stress in neonatal rat cardiomyocytes (NRCM).

Oxidative stress was quantified in NRCM cells measuring the glutathione level and the activity of PARylation processes. The decreased GSH level and increased auto-PARylation of PARP-1 enzyme showed that in hydrogen peroxide-stressed cells a significant oxidative stress is present. Both unfavorable changes could be diminished by pharmacological PARP-inhibition using L-2286. (Fig. 5). Mitochondria form a dynamic network in the cell, which is determined by the balance of fusion-fission processes. During oxidative stress, the mitochondrial network becomes fragmented, which has a central role in the cellular survival. Imbalanced mitochondrial dynamics are associated with a range of diseases that are broadly characterized by impaired mitochondrial function and increased cell death [40]. L-2286 treatment prevented the oxidative stress-induced mitochondrial fragmentation in NRCM cells (Fig. 6). In the background of this phenomenon, increased amount of fusion proteins (Opa1, Mfn2) could be seen in stressed NRCMs receiving PARP-inhibitor (Fig. 7). However, the expression level of fission mediators (Fis1, Drp1) were decreased by L-2286 treatment (Fig. 8). The activation and mitochondrial translocation of Drp1 is regulated by the phosphorylation of Drp1. Phosphorylation of Drp1 at

![Fig. 11. The effect of L-2286 treatment on the oxygen consumption rate in NRCM cells. (A) oxygen consumption rate (OCR) in NRCM cells, measured by Seahorse XFp Analyzer. (B) Basal respiration, maximal respiration and spare respiratory capacity in NRCM cells. (C) Proton leak and ATP production ability in NRCM cells. Group of cells: Control: cells without any treatment, Control + L-2286: cells incubated with 10 μM L-2286 for 0.5 h, H₂O₂: cells stressed with 150 μM H₂O₂ for 0.5 h, H₂O₂ + L-2286: cells stressed with 150 μM H₂O₂ and treated with 10 μM L-2286 for 0.5 h. Values are mean ± S.E.M, (n = 4). **p < 0.01 vs. Control group, *p < 0.05 vs. Control group, #p < 0.05 vs. H₂O₂ group.](image-url)
Serine 616 promotes mitochondrial fission, but Drp1 Serine 637 phosphorylation inhibits the activity and translocation of Drp1 to the mitochondria [41,42]. L-2286 treatment caused significant decrease in the phosphorylation of Drp1 at Serine 616, while an increase in the Drp1 phosphorylation at Serine 637 (Fig. 8). In accordance with this result, PARP-inhibition retained Drp1 in the cytosolic fraction despite oxidative stress, while the level of Drp1 in the mitochondrial fraction was significantly lower than in non-treated stressed cardiomyocytes (Fig. 9). These results suggest that L-2286 treatment can reduce mitochondrial fission as the translocation and anchorage of Drp1 to the outer mitochondrial membrane is diminished. Due to PARP-1 inhibition, the mitochondrial Opa1 content regulating the integrity and fusion of inner mitochondrial membranes was decreased.
membranes was increased (Fig. 9).

The maintenance of physiological mitochondrial structure through shifting mitochondrial dynamics toward the fusion, yields in a normal mitochondrial membrane potential despite oxidative stress [43,44]. Therefore, the above-mentioned favorable effects of L-2286 treatment on mitochondrial structure and fission-fusion processes result in preserving physiological mitochondrial membrane potential that is essential in the normal mitochondrial function (Fig. 10). Thus L-2286 treatment reverted the oxidative stress-induced decrease in mitochondrial function that was determined by a Seahorse XFp Analyzer. PARP-inhibition improved the spare respiratory capacity, which is a measure of the ability of the cell to respond to increased energy demand or under stress, and the ATP production ability in NRMC cells despite the presence of oxidative stress (Fig. 11).

Mitochondrial respiratory chain complexes are encoded on mtDNA, which is particularly sensitive to oxidative stress [35,45]. Our results suggested that hydrogen-peroxide caused mtDNA breaks, which hinders the transcription of genes coding the proteins of electron transport chain (ETC) [46]. In L-2286 treated NRMCs significantly less DNA breaks were observed, therefore it can be stated that PARP-inhibition can maintain the integrity of mitochondrial genome, therefore it can maintain the normal production of mitochondrial ETC complexes in stressed cells (Fig. 13).

The mitochondrial biogenesis can also be an important factor of energy production in cells [47]. It was found that mitochondrial content characterized by the amount of VDAC protein and by the citrate synthase activity was decreased due to oxidative stress and this could be reverted by L-2286 treatment (Fig. 12). The relative DNA content of ETC was significantly increased due to PARP-inhibitor treatment showing an enhanced cellular mitochondrial content in L-2286-treated cells. Mitochondrial biogenesis is regulated among others by the activation of PGC-1α via CREB activation. In oxidative stress situations L-2286 treatment induces activation of Akt protein, which promotes cell survival. A growing body of recent evidence has suggested that the activated Akt provides an activating phosphorylation (Ser133) to the CREB protein. The PGC1α gene promoter region exhibits a well-conserved binding site for CREB, which drives PGC1α expression after its activation [48-50]. In stressed NRMC cells L-2286 caused a marked elevation in the amount and function of both regulator proteins.

We have found that PARP-inhibitor treatment exerted wide-range positive effects on mitochondria during stress situations. PARP-inhibition shifted the mitochondrial dynamics toward fusion, increased biogenesis yielding in higher cellular mitochondrial content. Moreover, the ultrastructure and function of mitochondria were also preserved. All these effects can be at least partly in the background of its antioxidant, cyto- and cardioprotective effect.

5. Conclusion

In conclusion, pharmacological PARP-inhibition prevents cardiomyocytes against both chronic low-intensity oxidative stress as well as against acute, extensive oxidative damage by its mitochondrial protective effect. Modulation of mitochondrial dynamics and biogenesis can be a promising therapeutic target in the prevention and treatment of hypertension-induced myocardial remodeling and heart failure.

Author agreement

The authors have approved of and have agreed to submit the manuscript to this journal.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This study was supported by the Hungarian National Research Foundations Grant (GINOP-2.3.2-15-2016-00048) and the Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary, within the framework of the 1st thematic programme of the University of Pécs (2020-4.1.1-TKP2020).

References


